It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Reporter proteins have become an indispensable tool in biomedical research. However, exogenous introduction of these reporters into mice poses a risk of rejection by the immune system. Here, we describe the generation, validation and application of a multiple reporter protein tolerant ‘Tol' mouse model that constitutively expresses an assembly of shuffled reporter proteins from a single open reading frame. We demonstrate that expression of the Tol transgene results in the deletion of CD8+ T cells specific for a model epitope, and substantially improves engraftment of reporter-gene transduced T cells. The Tol strain provides a valuable mouse model for cell transfer and viral-mediated gene transfer studies, and serves as a methodological example for the generation of poly-tolerant mouse strains.
Bresser and Dijkgraaf et al. develop the ‘Tol’ strain, a genetically modified mouse model that expresses a range of shuffled reporter and modifier proteins from a single open reading frame. This strain is immunologically tolerant to these reporter and modifier proteins, providing a valuable model system for cell transfer studies and virus-mediated gene transfer studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 The Netherlands Cancer Institute, Division of Molecular Oncology & Immunology, Oncode Institute, Amsterdam, The Netherlands (GRID:grid.430814.a)
2 The Netherlands Cancer Institute, Mouse Clinic for Cancer and Aging research (MCCA) Transgenic Facility, Amsterdam, The Netherlands (GRID:grid.430814.a)
3 The Netherlands Cancer Institute, Animal Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a)
4 University of Freiburg, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9); University of Freiburg, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9)
5 Leiden University Medical Center, Department of Medical Oncology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
6 The Netherlands Cancer Institute, Division of Molecular Oncology & Immunology, Oncode Institute, Amsterdam, The Netherlands (GRID:grid.430814.a); Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)